Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51.
BACKGROUND:Chagas Disease, a WHO- and NIH-designated neglected tropical disease, is endemic in Latin America and an emerging infection in North America and Europe as a result of population moves. Although a major cause of morbidity and mortality due to heart failure, as well as inflicting a heavy ec...
Main Authors: | Shamila S Gunatilleke, Claudia M Calvet, Jonathan B Johnston, Chiung-Kuang Chen, Grigori Erenburg, Jiri Gut, Juan C Engel, Kenny K H Ang, Joseph Mulvaney, Steven Chen, Michelle R Arkin, James H McKerrow, Larissa M Podust |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3409115?pdf=render |
Similar Items
-
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
by: Chiung-Kuang Chen, et al.
Published: (2009-01-01) -
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
by: Chiung-Kuang Chen, et al.
Published: (2010-04-01) -
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).
by: Anjan Debnath, et al.
Published: (2017-12-01) -
Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
by: Caio H. Franco, et al.
Published: (2020-08-01) -
4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
by: Claudia Magalhaes Calvet, et al.
Published: (2017-12-01)